In:
Advances in Digestive Medicine, Wiley, Vol. 1, No. 4 ( 2014-12), p. 112-117
Abstract:
Clinical trials and real‐world data confirm the efficacy of entecavir treatment for chronic hepatitis B (CHB); however, the factors associated with a favorable response remain unknown. Methods In a retrospective multicenter study, 132 treatment‐naïve hepatitis B e antigen (HBeAg)‐positive CHB patients (71% male; median age, 40.2 years) received entecavir therapy for 〉 2 years. At baseline, 15% of these patients had cirrhosis. The primary endpoint was HBeAg loss at 2 years of entecavir treatment. Results The rates of serum alanine aminotransferase (ALT) normalization at treatment Year 1 and Year 2 were 86% and 88%, respectively. The cumulative rate of HBeAg loss at treatment Year 1 and Year 2 were 17% and 33.3%, respectively. The rates of undetectable levels of serum hepatitis B virus (HBV) deoxyribonucleic acid (DNA) at treatment Year 1 and Year 2 were 64% and 80.8%, respectively. In univariate analysis, HBeAg loss at 2 years was associated with a young age (≤35 years; p = 0.007) and a high baseline ALT level ( p 〈 0.001). Multivariate analysis after adjusting for age, sex, and ALT level [ 〉 5 times the upper limit of normal (ULN)] showed that a young age (odds ratio, 2.66; 95% confidence interval, 1.2–5.92) and male sex (odds ratio, 0.36; 95% confidence interval, 0.16–0.83) were independent factors associated with HBeAg loss at 2 years of therapy. Conclusion Two‐year entecavir therapy has good biochemical and virologic responses; however, the rate of HBeAg loss is modest in HBeAg‐positive CHB patients. A young age (i.e., ≤35 years) and female sex were also associated with a better serologic response.
Type of Medium:
Online Resource
ISSN:
2351-9797
,
2351-9800
DOI:
10.1016/j.aidm.2014.03.003
Language:
English
Publisher:
Wiley
Publication Date:
2014
detail.hit.zdb_id:
2830898-0
Permalink